Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
SS Innovations International, Inc. showcased SSi Mantra and SSi MantrAsana in successful telesurgeries during October 2026 conferences; as of October 23, 2026, 205 telesurgeries had been performed with SSi Mantra.
SS Innovations International, Inc. submitted an October 5, 2026 response to an FDA request for additional information about its 510(k) submission for SSi Mantra, including clinical, human factors and bridging-study data; FDA review is expected in the first quarter of 2027.
SS Innovations International, Inc. issued a secured convertible promissory note with $21,025,000.00 original principal and 8.75% annual interest, maturing thirty-six (36) months after the Purchase Price Date.
SS Innovations International, Inc. furnished an updated October 2026 Company Presentation for communications with shareholders and the investment community, highlighting advanced, affordable and accessible surgical robotic solutions.
